key: cord-1026531-fvdcgt9n
authors: Nayak, Kaustuv; Gottimukkala, Kamalvishnu; Kumar, Sanjeev; Reddy, Elluri Seetharami; Edara, Venkata Viswanadh; Kauffman, Robert; Floyd, Katharine; Mantus, Grace; Savargaonkar, Deepali; Goel, Pawan Kumar; Arora, Satyam; Rahi, Manju; Davis, Carl W.; Linderman, Susanne; Wrammert, Jens; Suthar, Mehul S.; Ahmed, Rafi; Sharma, Amit; Murali-Krishna, Kaja; Chandele, Anmol
title: Characterization of neutralizing versus binding antibodies and memory B cells in COVID-19 recovered individuals from India
date: 2021-03-05
journal: Virology
DOI: 10.1016/j.virol.2021.02.002
sha: 06ec898736ba3d85b3522aa2d762f82e779804fb
doc_id: 1026531
cord_uid: fvdcgt9n

India is one of the most affected countries by COVID-19 pandemic; but little is understood regarding immune responses to SARS-CoV-2 in this region. Herein we examined SARS-CoV-2 neutralizing antibodies, IgG, IgM, IgA and memory B cells in COVID-19 recovered individual from India. While a vast majority of COVID-19 recovered individuals showed SARS-CoV-2 RBD-specific IgG, IgA and IgM antibodies (38/42, 90.47%; 21/42, 50%, 33/42, 78.57% respectively), only half of them had appreciable neutralizing antibody titers. RBD-specific IgG, but not IgA or IgM titers, correlated with neutralizing antibody titers and RBD-specific memory B cell frequencies. These findings have timely significance for identifying potential donors for plasma therapy using RBD-specific IgG assays as surrogate measurement for neutralizing antibodies in India. Further, this study provides useful information needed for designing large-scale studies towards understanding of inter-individual variation in immune memory to SARS CoV-2 natural infection for future vaccine evaluation and implementation efforts.

The recombinant SARS-CoV-2 RDB gene was cloned, expressed, purified and ELISAs were 127 performed as previously described (31). Briefly, purified RBD was coated on MaxiSorp 128 plates (Thermo Fisher, #439454) at a concentration of 1 ug/mL in 100 uL phosphate-129 buffered saline (PBS) at 4 o C overnight. The plates were washed extensively with PBS 130 containing 0.05% Tween-20. Three-fold serially diluted plasma was added to the plates and 131 incubated at room temperature for 1hr. After incubation, the plates were washed and the 132 SARS-CoV-2 RBD specific IgG, IgM, IgA signals were detected by incubating with 133 horseradish peroxidase (HRP) conjugated -anti-human IgG (Jackson ImmunoResearch 134

Labs, #109-036-098), IgM (Jackson ImmunoResearch Labs, #109-036-129), or IgA (Jackson 135

ImmunoResearch Labs, #109-036-011). Plates were then washed thoroughly and 136 developed with o-phenylenediamine (OPD) substrate (Sigma, #P8787) in 0.05M 137 phosphate-citrate buffer (Sigma, #P4809) pH 5.0, containing with 0.012% hydrogen 138 peroxide (Fisher Scientific, #18755) just before use. Absorbance was measured at 490 nm. 139

Purified RBD protein (100 ug) was labeled with Alexa Fluor 488 using microscale protein 141 labeling kit (Life Technologies, #A30006) as per manufacturer's protocol. PBMC's were 142 stained with RBD-Alexa Fluor 488 for 1 hour at 4 o C, followed by washing with PBS 143 containing 0.25% Fetal Bovine Serum (FBS), and incubation with efluor780 Fixable 144 Viability (Live Dead) dye (Life Technologies, #65-0865-14) and anti-human CD3, CD19, 145 CD27, CD38 and IgD antibodies (BD Biosciences) for 30 minutes. Cells were washed twice 146 with FACS buffer and acquired on BD LSR Fortessa X20. Data was analyzed using FlowJo 147 7 software 10. SARS-CoV-2 RBD-specific memory B cells were identified in cells positive for 148 CD19, CD20, CD27 that were negative for IgD and CD3. 149 150 IgG ELISA for SARS-CoV-2 whole virus preparation 151 SARS-CoV-2 antigen specific IgG was detected using a commercially available assay 152 (COVID-Kavach ELISA tests kit, Zydus diagnostics), which measures responses to antigen 153 concentrated from gamma-irradiated SARS-CoV-2-infected tissue culture fluid as per the 154 manufacturer's instructions (32, 33) . 155

Neutralization titers to SARS-CoV-2 were determined as previously described (31) in the duplicate wells incubated at the highest dilution of the respective specimen). 175

Statistical analysis was performed using GraphPad prism 8.0 software. Non-parametric t 177 test (Mann-Whitney) was used to calculate the differences between groups. Non-178 parametric Spearman's correlation coefficient (r) was used to calculate correlation 179 between groups.

A p value of <0.05 was considered as significant. 

The demographic profile of COVID-19 recovered individuals recruited for this study is 185 shown in Table 1 . All subjects were at least 3.6 weeks past their initial SARS-CoV-2 186 positive diagnosis. RBD-specific ELISA curves for IgG, IgA and IgM at different dilutions of 187 plasma in pre-pandemic healthy versus COVID-19 recovered individuals is shown in Figure  188 1. RBD-specific responses were highly elevated in COVID-19 recovered individuals as 189 compared to pre-pandemic healthy controls ( Figure 1A 

To assess plasma neutralizing titers from COVID-19 convalescent individuals, we 201 performed a live virus neutralization assay using a focus-reduction neutralization 202 mNeonGreen (FRNT-mNG) assay (31). The neutralizing activity at different dilutions of 203 plasma for pre-pandemic healthy individuals ( Figure 3A ) and COVID-19 recovered 204 individuals is shown in (Figure 3B ). Figure 3C shows FRNT-mNG50 titers calculated based 205 on the plasma dilution that neutralized 50% of the virus. While all pre-pandemic healthy 206 individuals had undetectable FRNT-mNG50 titers, only half of the COVID-19 recovered 207 individuals showed 50% or more neutralization even at a 1:20 dilution of plasma. Similar 208 to RBD-specific IgG titers, the FRNT-mNG50 titers were heterogeneous with the latter 209 reaching titers as high as 682 ( Figure 3C) . Plasma infusion therapy has recently been started in India as an intervention therapy for 219 COVID-19. For this, plasma donors are being typically identified by the presence of IgG to 220 SARS-CoV-2 by commercial ELISA tests (40). One of these tests detects IgG towards viral 221 antigens concentrated from gamma-irradiated SARS-CoV-2-infected tissue culture fluid (32, 222 33). It was therefore of interest to examine the correlation between neutralization titers 223 and IgG responses measured using this test. We observed that, of the 42 COVID-19 224 recovered individuals tested, 33 were IgG positive whereas 9 were below the assay cut off 225 ( Figure 5A ). Of the 9 individuals that were below cut off, 4 also tested negative by the RBD-226 specific IgG ELISA ( Table 2) . All of the samples from the pre-pandemic healthy individuals 227 were below the limit of detection. As expected, the IgG values obtained by whole virus-228 based ELISA did not show as robust a correlation (r=0.56) with neutralizing antibody titers 229 ( Figure 5B ) as compared to those observed with RBD-specific IgG titers (r=0.83) (Figure 4 , 230 left graph). 231 232

While circulating neutralizing antibodies help prevent re-infection by viruses, memory B 234 cells allow for rapid production of new antibodies in case of re-infection. To address 235 whether the COVID-19 recovered individuals generated memory B cells, we enumerated 236 RBD-specific memory B cells using fluorescently conjugated RBD antigen. An example of 237 the flow cytometric gating strategy and RBD staining among the gated memory B cells is 238 shown in Figure 6A and 6B. Figure 6C shows the frequency of RBD-specific memory B 239 cells in a subset of the individuals where sufficient PBMCs were available. Though we found 240 that there was substantial inter-individual variation in the frequency of SARS-CoV-2 RBD-241 specific memory B cells, their frequencies modestly correlated with RBD-specific IgG titers. Research, New Delhi. All subjects were SARS-CoV-2 PCR positive at the time of initial diagnosis and were PCR negative when recruited for this study at 4.8 -11 weeks post initial diagnosis.

Timeline: WHO's COVID-19 response. 385 2. Ministry of Health and Family Welfare GoI. 2020. COVID-19 INDIA as on

Vaccine Candidates against Coronavirus 388 Infections. Where Does COVID-19 Stand? Viruses 12

SARS-CoV-2 Vaccines: Status Report

Approaches and Challenges in SARS-CoV-2

A Review on Remdesivir: A Possible 394 Promising Agent for the Treatment of COVID-19

Progress in Developing Inhibitors of SARS-CoV-2 3C-Like 397

Emerging 399 Therapeutic Modalities against COVID-19

Current 401 coronavirus (SARS-CoV-2) epidemiological, diagnostic and therapeutic approaches: 402 An updated review until

Utilizing drug repurposing against COVID-19

Efficacy, limitations, and challenges

Current updates on the European and WHO 407 registered clinical trials of coronavirus disease 2019 (COVID-19)

Risk-benefit analysis on the 411 clinical significance of convalescent plasma therapy in the management of COVID-19

Convalescent 422 Plasma Therapy on Patients with Severe or Life-Threatening COVID-19: A Metadata 423 Analysis

Treatment of COVID-19 Patients with Convalescent 427 Plasma Reveals a Signal of Significantly Decreased Mortality

Treatment of 5 Critically Ill Patients With COVID-432 19 With Convalescent Plasma

Treatment with 434 convalescent plasma for COVID-19 patients in Wuhan

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Structures of Human Antibodies 444 Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of 445 Antibodies

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the 450 ACE2 receptor

Potent neutralizing antibodies 454 against multiple epitopes on SARS-CoV-2 spike

COVID-19 456 pandemic: Insights into structure, function, and hACE2 receptor recognition by 457 SARS-CoV-2

2020. A highly specific and sensitive serological 463 assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with 464 neutralization

Structural and Functional Basis of SARS-CoV-2 Entry by 467 Using Human ACE2

Potently neutralizing human antibodies that block SARS-CoV-2 473 receptor binding and protect animals

Standard Operating Procedure For Detection of 2019 novel 482 coronavirus (2019-nCoV) in suspected human cases by rRT-PCR : confirmation 483 assay

Rapid generation of neutralizing antibody responses in 490 COVID-19 patients

Comparative Evaluation of SARS-CoV-2 IgG Assays in India

Covid Support Team: Pawar S 498 PSSVNVMVMBJASPMRKRSDK. 2020. Development of indigenous IgG ELISA for the 499 detection of anti-SARS-CoV-2 IgG

Viridot: An automated virus plaque (immunofocus) counter for the 503 measurement of serological neutralizing responses with application to dengue virus

The neutralizing role of IgM during early 506 Chikungunya virus infection

A cross-reactive human IgA monoclonal 511 antibody blocks SARS-CoV-2 spike-ACE2 interaction

Potent neutralizing serum immunoglobulin A (IgA) in human 514 immunodeficiency virus type 2-exposed IgG-seronegative individuals

Abhishake 564 Lahiri, Debaleena Bhowmik, Janani Srinivasa Vasudevan, Ranjeet Maurya

Clinical and 571 immunological benefits of convalescent plasma therapy in severe COVID-19: 572 insights from a single center open label randomised control trial

Doymaz 575 MZ. 2020. Discordance between Serum Neutralizing Antibody Titers and the 576 Recovery from COVID-19

T cell responses in patients with COVID-19

Targets of T 582 Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and 583 Unexposed Individuals

Immune Parameters and COVID-19 Infection -586 Associations With Clinical Severity and Disease Prognosis

Viral Persistence Induces 589

Antibody Inflation without Altering Antibody Avidity

Initial viral load determines the magnitude of 592 the human CD8 T cell response to yellow fever vaccination

Role of host immune response and viral load in the differential 596 outcome of pandemic H1N1 (2009) influenza virus infection in Indian patients

Correlation of plasma viral loads and 599 presence of Chikungunya IgM antibodies with cytokine/chemokine levels during 600 acute Chikungunya virus infection

Buying time-the immune system 602 determinants of the incubation period to respiratory viruses

Deciphering the Role of Host Genetics in 605 Susceptibility to Severe COVID-19

New insights into genetic susceptibility of COVID-19: an ACE2 and 608 TMPRSS2 polymorphism analysis

The Role of Host 610 Genetic Factors in Coronavirus Susceptibility: Review of Animal and Systematic 611 Review of Human Literature

Lauren 616 Martinez

Longitudinal evaluation and decline of 620 antibody responses in SARS-CoV-2 infection

Serologic Response to SARS-CoV-2 in COVID-19 Patients with Different Severity

Antibody Profiles in Mild and Severe Cases of COVID-19

Table 2. Individual characteristics of the COVID-19 recovered subjects

Zydus) using 1:100 dilution of plasma as per by the manufacturer's recommendation

Neutralization titres: Neutralization assay were performed using 3 fold dilution of plasma, starting at 1:20 up to 1:43740. Limit of detection for FRNT-mNG

J o u r n a l P r e -p r o o f